Bioscience and pharmaceutical Economic Development Health Care Insider Only New Castle County News Start Up

Synnovation Therapeutics launches with $102M

Katie Tabeling January 29, 2024

WILMINGTON - A precision oncology startup based out of the Experimental Station in Wilmington has emerged with $102 million financing last week. Synnovation Therapeutics, led by CEO Wenqing Yao, completed Series A funding round led by Third Rock Ventures. The investment also included funds from Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management.

Want to Read More?

Paid DBT subscribers get unlimited access to all Insider content and much more. Learn more in our Insider FAQ.

Become an Insider Now

Already an Insider? Log In.

Tags:

🔒 Wilmington buys Gibraltar mansion for $900K

🔒 New loan program aims to help minority-owned small businesses

Del. Memorial Bridge to be fortified with barriers

Katie Tabeling April 15, 2024

Bowman tapped for White House trade advisory council

Katie Tabeling June 14, 2024

Matt Meyer Overlook Colony affordable housing Interfaith Community Housing of Delaware

Meyer wins Democrat primary, to face Ramone in November

Katie Tabeling September 10, 2024

AB&C moves to new Wilmington office

Jacob Owens May 18, 2023

Premier Digital Partners

WILMINGTON - A precision oncology startup based out of the Experimental Station in Wilmington has emerged with $102 million financing last week. [caption id="attachment_235569" align="alignright" width="239"]

The $102M funding will advance Synnovation’s clinical and preclinical pipeline for two drugs and other programs. | PHOTO COURTESY OF SYNNOVATION[/caption] Synnovation Therapeutics, led by CEO Wenqing Yao, completed Series A funding round led by Third Rock Ventures. The investment also included funds from Nextech, Lilly Asia Ventures, Sirona Capital and Cormorant Asset Management. The funding will advance Synnovation’s clinical and preclinical pipeline for two drugs, SNV1521 and SNV4818, among other programs. “At Synnovation, we have assembled a top-notch team dedicated to fostering a multidisciplinary and collaborative approach,” Yao said in a statement. “Our goal is to develop best-in-class therapies, ultimately aiming to enhance the lives of patients. We look forward to advancing in the clinic … as we continue to grow our potential best-in-class pipeline of agents.” Synnovation aims to lead the way on cutting edge research on combating solid tumors by finding genetic and pharmacologic vulnerabilities of cancer. The company is expected to start human testing on undisclosed cancers in the coming weeks. Yao spent 19 years at Incyte, where he eventually served as head of discovery chemistry before he left to launch Synnovation in 2021. The company’s co-founder, Liangxing Wu, worked alongside Yao at Incyte on research to create new molecules to aid treatments. Synnovation’s management team also led to discovery of four other drugs while working at Incyte, including Jakafi and Opzelura. Other Synnovation key leaders include other Incyte veterans Phillip Liu as senior vice president and head of biology and Kevin O’Hayer, the senior vice president and head of clinical development. Previously, Liu led a cell and molecular biology group that supported Incyte’s discovery pipeline and collaborated closely with Yao and Wu on small molecule programs. O’Hayer also developed clinical programs to treat inflammatory conditions and Covid-19. Synnovation Therapeutics also raised $69.9 million in December, making it the largest venture capital deal of the final quarter of the year, according to the latest Venture Monitor report from PitchBook and the National Venture Capital Association.

Synnovation Therapeutics launches with $102M

Want to Read More?

You Might also Like

Leave a Comment Cancel Comment

Premier Digital Partners

Newsletter Signup

Related Stories

ABOUT

NEWS INDUSTRY

SUBSCRIBE

FOLLOW US

Premier Digital Partners

Type to search

Synnovation Therapeutics launches with $102M

Share

Want to Read More?

You Might also Like

Leave a Comment Cancel Comment

Premier Digital Partners

Newsletter Signup

Related Stories

ABOUT

NEWS INDUSTRY

SUBSCRIBE

FOLLOW US

Premier Digital Partners